Cardiovascular Risk
New cardiovascular risk research from A. Pfutzner et al outlined
Published in Diabetes Week, February 25th, 2008
According to recent research published in the journal Hormone and Metabolic Research, "The aim of the study was to analyze the effect of pioglitazone (PIO) and simvastatin (SIMVA) on adiponectin and visfatin concentrations in nondiabetic patients with metabolic syndrome and increased risk for cardiovascular complications in a prospective randomized clinical trial. One-hundred twenty-five nondiabetic patients with increased cardiovascular risk [78 females, 47 males, age (mean +/- STD:58.6 +/- 7.8years, BMI:30.8 +/- 4.2(kg/m(2)] were included after randomization to PIO + lacebo, SIMVA + placebo, or PlO + SIMVA treatment for 3 months."
"At baseline and endpoint,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
Source: Diabetes Week (2008-02-25)
More Articles from Diabetes Week
- Diabetes
Active seniors curb health care costs - Cardiovascular Disease
Research from Tufts University reveals new findings on cardiovascular disease - Diabetes
Data on diabetes described by researchers at University of California - Diabetes
Report summarizes diabetes study findings from Yale University, Medical Department - Metabolism
Research reports on metabolism from S.M. Johansson and colleagues provide new insights - Microscopy
New microscopy research from National Institutes of Health outlined - More from this issue of Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
